Research
Hormonal
Estrogen and other sex hormones play a protective role in mitochondrial function and aging, with women showing higher mitochondrial gene expression and activity compared to men.
Hormones, particularly estrogen, significantly impact how your cells produce energy and age. Women naturally have more active mitochondria, which contributes to their longer lifespan. As estrogen levels drop after menopause, this protective effect diminishes, potentially accelerating certain aspects of aging. Maintaining metabolic health becomes crucial during this transition.
GoodSupportsHIGH confidence
Estrogens have been shown to influence mitochondrial function and exert protective effects, partly explaining why women have delayed mitochondrial aging compared to men.
Why this rating
Supported by multiple human and animal studies cited in the review.
Source
Sex differences in biological aging with a focus on human studies
Sara Hägg et al. · eLife · 2021
DOI 10.7554/elife.63425
narrative_reviewCited 419×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Women exhibit lower biological aging and greater longevity than men, evidenced by molecular biomarkers, higher mitochondrial function, and longer telomeres, despite experiencing higher frailty and worse health outcomes at the end of life.Good
- Telomere length is sexually dimorphic, with women having longer telomeres than men from birth, which may contribute to their longer lifespan, although the causal relationship is complex and influenced by genetics and stress.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →